DOI QR코드

DOI QR Code

Pathologic Response During Chemo-radiotherapy and Variation of Serum VEGF Levels Could Predict Effects of Chemo-Radiotherapy in Patients with Esophageal Cancer

  • Yu, Jing-Ping (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
  • Lu, Wen-Bin (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
  • Wang, Jian-Lin (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
  • Ni, Xin-Chu (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
  • Wang, Jian (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
  • Sun, Zhi-Qiang (Department of Radiation Oncology, Changzhou NO.2 People's Hospital) ;
  • Sun, Su-Ping (Department of Radiation Oncology, Changzhou NO.2 People's Hospital)
  • Published : 2015.03.04

Abstract

Background: To investigate the relationship between pathologic tumor response to concurrent chemoradiotherapy and variation of serum VEGF in patients with esophageal cancer. Materials and Methods: Forty six patients with esophageal cancer who were treated with concurrent chemo-radiotherapy were enrolled. Endoscopic and pathologic examination was conducted before and four weeks afterwards. Serum level of VEGF was documented before, four weeks later and after chemo-radiotherapy. The relationship between pathologic response and the variation of serum level of VEGF and its influence on the prognosis were investigated. Results: Serum level of VEGF decreased remarkably during and after chemo-radiotherapy in patients whose pathologic response was severe (F=5.393, 4.587, P(0.05). There were no statistical differences of serum VEGF level before, during and after chemo-radiotherapy for patients whose pathologic response was moderate or mild. There were 18 (85.7%), 7 (53.8%) and 6 patients (50.0%) whose serum VEGF level dropped in the severe, moderate and mild group, respectively, with significant differences among these groups (p=0.046). Two year survival rates of patients with severe, moderate and mild pathologic response were 61.9%, 53.8% and 33.3% respectively, and no statistically difference between severe and mild group regarding OS (p=0.245) was tested. Conclusions: Tumor pathologic response during chemo-radiotherapy and the changes of serum VEGF lever could predict curative effects of chemo-radiotherapy in patients with esophageal cancer.

Keywords

Esophageal carcinoma;pathology response;vascular endothelial growth factor;prognosis

Acknowledgement

Supported by : Health Department

References

  1. Angelescu C, Burada F, Ioana M, et al (2013). VEGF-A and VEGF-B mRNA expression in gastro-oesophageal cancers. Clin Transl Oncol, 15, 313-20. https://doi.org/10.1007/s12094-012-0923-y
  2. Brun E, Zatterstrom U, Kjellen E, et al (2001). Prognostic value of histopathological response to radiotherapy and microvessel density in oral squamous cell carcinomas. Acta Oncol, 40, 491-6. https://doi.org/10.1080/028418601750288226
  3. Cellini F, and Valentini V (2014). Targeted therapies in combination with radiotherapy in oesophageal and gastroesophageal carcinoma. Curr Med Chem, 21, 990-1004. https://doi.org/10.2174/09298673113209990236
  4. Crehange G, Maingon P, Peignaux K, et al (2007). Phase III trial of protracted compared with split-course chemoradiation for esophageal carcinoma: Federation Francophone de Cancerologie Digestive 9102. J Clin Oncol, 25, 4895-901. https://doi.org/10.1200/JCO.2007.12.3471
  5. Jiang JT, Zhang LF, Zhou B, et al (2012). Relationships of uPA and VEGF expression in esophageal cancer and microvascular density with tumorous invasion and metastasis. Asian Pac J Cancer Prev, 13, 3379-83. https://doi.org/10.7314/APJCP.2012.13.7.3379
  6. Limaverde-Sousa G, Sternberg C, and Ferreira CG (2014). Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents. Cancer Treat Rev, 40, 548-57. https://doi.org/10.1016/j.ctrv.2013.11.009
  7. Liu J, Huang XE (2014). Efficacy of bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation. Asian Pac J Cancer Prev, 15, 10241-4.
  8. Ou GF, Wang M, Wang LH, et al (2003). [Relation between pathologic tumor response to preoperative radiotherapy and the prognosis in patients with esophageal carcinoma]. Zhonghua Zhong Liu Za Zhi, 25, 278-81.
  9. Peng J, Shao N, Peng H, and Chen LQ (2013). Prognostic significance of vascular endothelial growth factor expression in esophageal carcinoma: a meta-analysis. J BUON, 18, 398-406.
  10. Qian YD, Xu X, Wang L, et al (2014). Clinical safety of chemotherapy for elderly cancer patients complicated with hypertension. Asian Pac J Cancer Prev, 15, 9875-7. https://doi.org/10.7314/APJCP.2014.15.22.9875
  11. Shibata Y, Haruki N, Kuwabara Y, et al (2002). Chfr expression is downregulated by CpG island hypermethylation in esophageal cancer. Carcinogenesis, 23, 1695-9. https://doi.org/10.1093/carcin/23.10.1695
  12. Srivastava VK, Gara RK, Rastogi N, et al (2014). Serum vascular endothelial growth factor-A (VEGF-A) as a biomarker in squamous cell carcinoma of head and neck patients undergoing chemoradiotherapy. Asian Pac J Cancer Prev, 15, 3261-5. https://doi.org/10.7314/APJCP.2014.15.7.3261
  13. Stahl M, Walz MK, Stuschke M, et al (2009). Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol, 27, 851-6. https://doi.org/10.1200/JCO.2008.17.0506
  14. Tian GY, Miu M, Huang XE (2014).Systematic analysis of pemetrexed-based chemoradiotherapy for patients with locally advanced or metastatic esophageal cancer. Asian Pac J Cancer Prev, 15, 8475-8. https://doi.org/10.7314/APJCP.2014.15.19.8475
  15. Wang W, Sun QK, He YF, et al (2014). Overexpression of periostin is significantly correlated to the tumor angiogenesis and poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol, 7, 593-601.
  16. Xiao Y, Liu J, Huang XE, et al (2014).Clinical study on fluvoxamine combined with oxycodone prolonged-release tablets in treating patients with moderate to severe cancer pain. Asian Pac J Cancer Prev, 15, 10445-9.
  17. Yu J, Liu F, Sun Z, et al (2011). The enhancement of radiosensitivity in human esophageal carcinoma cells by thalidomide and its potential mechanism. Cancer Biother Radiopharm, 26, 219-27. https://doi.org/10.1089/cbr.2010.0897

Cited by

  1. Effects of definitive chemoradiation on circulating immunologic angiogenic cytokines in head and neck cancer patients vol.4, pp.1, 2016, https://doi.org/10.1186/s40425-016-0138-9